ATOSSA THERAPEUTICS, INC. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount
ATOSSA THERAPEUTICS, INC. (ATOS) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount of $3.00 thousand for the 12-month period ending 2024-12-31, per its 10-K filed 2026-03-25.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment · last filed 2026-03-25
- ATOSSA THERAPEUTICS, INC. effective income tax rate reconciliation, nondeductible expense, research and development, amount for fiscal 2024 was $3.00K, a 66.67% decline from fiscal 2023.
- ATOSSA THERAPEUTICS, INC. effective income tax rate reconciliation, nondeductible expense, research and development, amount for fiscal 2023 was $9.00K, a 97.44% decline from fiscal 2022.
- ATOSSA THERAPEUTICS, INC. effective income tax rate reconciliation, nondeductible expense, research and development, amount for fiscal 2022 was $351.00K.
- ATOSSA THERAPEUTICS, INC. effective income tax rate reconciliation, nondeductible expense, research and development, amount for fiscal 2021 was $0.00.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount 12 month |
|---|---|
| 2024-12-31 | $3.00K 10-K · filed 2026-03-25 |
| 2023-12-31 | $9.00K 10-K · filed 2025-03-25 |
| 2022-12-31 | $351.00K 10-K · filed 2024-04-01 |
| 2021-12-31 | $0.00 10-K · filed 2023-03-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |